Results 261 to 270 of about 943,185 (296)

Biomaterial Strategies for Targeted Intracellular Delivery to Phagocytes

Advanced Functional Materials, EarlyView.
Phagocytes are essential to a functional immune system, and their behavior defines disease outcomes. Engineered particles offer a strategic opportunity to target phagocytes, harnessing inflammatory modulation in disease. By tuning features like size, shape, and surface, these systems can modulate immune responses and improve targeted treatment for a ...
Kaitlyn E. Woodworth, Neal I. Callaghan, Locke Davenport Huyer   +2 more
wiley   +1 more source

Digital twins for chronic lung diseases. [PDF]

Eur Respir Rev
Gonsard A, Genet M, Drummond D.
europepmc   +1 more source

Recognition of Idiopathic Inflammatory Myopathies Underlying Interstitial Lung Diseases. [PDF]

Diagnostics (Basel)
Morina G, Sambataro D, Libra A, Palmucci S, Colaci M, La Rocca G, Ferro F, Carli L, Baldini C, Liuzzo SV, Vancheri C, Sambataro G.   +11 more
europepmc   +1 more source

Respiratory assessment and management of newborns and children with congenital lung diseases: a cohort study. [PDF]

Ital J Pediatr
Porcaro F, Coretti A, Pardi V, Aloi IP, Conforti A, Petreschi F, Cutrera R.   +6 more
europepmc   +1 more source

Occluding mucous airway plugs in patients with obstructive lung diseases: a new treatable trait? [PDF]

ERJ Open Res
Agustí A, Aliberti S, Blasi F, Miravitlles M, Papi A.   +4 more
europepmc   +1 more source

A comprehensive review on the cellular mechanism of traditional Chinese medicine in the treatment of pediatric lung diseases. [PDF]

Bioimpacts
Wang Y.
europepmc   +1 more source

Association Between Air Quality Index (AQI) Variability and Hospital Admissions for Lung Diseases: A Longitudinal Study

Ahmed MT, Hossain MR.
europepmc   +1 more source

Corrigendum: Obesity paradox in pulmonary hypertension secondary to chronic lung diseases. [PDF]

Chin Med J (Engl)
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Mild parenchymal lung disease is still lung disease

European Respiratory Journal, 2020
PAH patients with mild parenchymal disease/low DLCO should be considered as group 3 patients with pulmonary vascular phenotypehttps://bit.ly ...
Joan Albert Barberà, Laurent Godinas, Sergio Harari, David Montani, David Montani   +4 more
openaire   +7 more sources